La cadena de opciones muestra datos clave de las opciones de acciones de Revolution Medicines a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Revolution Medicines..

Revolution Medicines (NASDAQ:RVMD) Bolsa, Cadena de Opciones

Revolution Medicines

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Revolution Medicines, Inc. - Common Stock

Revolution Medicines Inc

D. Boral Capital analyst Jason Kolbert maintains VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $5 price target.

News

Price Target

Analyst Ratings

VNRX

D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target

HC Wainwright &amp; Co. analyst Robert Burns downgrades SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) from Buy to Neutral and lowers the price target from $74 to $47.

Downgrades

SWTX

HC Wainwright & Co. Downgrades SpringWorks Therapeutics to Neutral, Lowers Price Target to $47

Americans spooked by headlines about Social Security's shaky finances are <a href="https://www.benzinga.com/personal-finance/25/04/45034325/americans-rush-to-claim-social-security-early-amid-growing-fears-of-cuts-and-agency-instability-under-trump-administration">racing to file claims</a> at 62, even though experts say the math still favors patience.
What To Know: The program's trustees warn that the retirement trust fund could run <a href="https://www.ssa.gov/policy/trust-funds-summary.html">dry by 2033</a>, after which only 79 percent of scheduled benefits would be paid. Yet financial planners argue that grabbing smaller checks today can backfire if you live into your 80s or 90s.
Fear is real: 64 percent of adults now <a href="https://www.allianzlife.com/about/newsroom/2025-Press-Releases/Americans-Are-More-Worried-About-Running-Out-of-Money-Than-Death?utm_source=chatgpt.com">worry more</a> about outliving their money than dying, with Social Security shortfalls ranking just behind inflation as the top stressor, according to a study by Allianz Life. Benefits replace only about 40 percent of <a href="https://www.ssa.gov/policy/docs/ssb/v68n2/v68n2p1.html">preretirement income</a> on average, and agency <a href="https://www.benzinga.com/news/25/04/44999167/social-security-payments-could-face-interruptions-in-may-warns-former-commissioner-martin-omalley-ne">staffing cuts</a> and long wait times have eroded public confidence.
See also: <a href="https://www.benzinga.com/markets/25/04/45091467/trump-can-either-have-his-cake-or-eat-it-economist-justin-wolfers-calls-out-presidents-fundamental-incoherence-on-trade-deals-and-tariffs">Trump Can Either Have His Cake Or Eat It, Economist Justin Wolfers Calls Out President&#8217;s &#8216;Fundamental Incoherence&#8217; On Trade Deals And Tariffs</a>
Still, the incentives to delay are sizable. Claiming at 62 trims monthly checks by <a href="https://www.ssa.gov/benefits/retirement/planner/agereduction.html">roughly 25 percent</a> for those whose full retirement age (FRA) is 66 and by 30 percent for an FRA of 67. Most retirees take the hit anyway, <a href="https://crsreports.congress.gov/product/pdf/R/R44670/14">according</a> to the Congressional Research Service. Waiting past FRA boosts benefits 8 percent per year until age 70 — a 24 percent to 32 percent jump that insures against <a href="https://www.ssa.gov/benefits/retirement/planner/delayret.html">longevity risk</a>.
Delaying is especially valuable for married couples and anyone worried about future inflation shocks, Vanguard researchers <a href="https://corporate.vanguard.com/content/dam/corp/research/pdf/claiming_social_security_early_spectrum_breakeven_longevity_risks.pdf">find</a>. Meanwhile, Donald Trump has repeated that he "won't cut current retirees' benefits," <a href="https://www.benzinga.com/government/25/04/45064937/donald-trump-threatens-to-veto-any-gop-bill-that-touches-medicaid-or-social-security-if-it-cuts-it-i-would-not-approve">reassuring older voters</a> even as Congress debates new taxes or modest trims for younger workers.
Bottom line, planners say: unless poor health shortens your horizon, every month you wait buys larger lifetime protection — and that may matter more than beating Washington's next funding fix.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/tech/25/04/45096452/mark-zuckerberg-denies-tilt-towards-donald-trump-says-big-tech-must-work-with-whoever-is-in-power-describes-last-decade-as-painful-maturation-process">Mark Zuckerberg Denies Tilt Towards Donald Trump, Says Big Tech Must Work With &#8216;Whoever&#8217; Is In Power, Describes Last Decade As &#8216;Painful Maturation Process&#8217;</a>

Personal Finance

Social Security Panic Is Premature, Experts Say: Delaying Claims Still Yields Bigger Checks Despite 2033 Trust-Fund Clock

Graham Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHC#NYSE">GHC</a>) reported quarterly earnings of $11.64 per share which beat the analyst consensus estimate of $11.29 by 3.1 percent. This is a 3.56 percent increase over earnings of $11.24 per share from the same period last year. The company reported quarterly sales of $1.17 billion which missed the analyst consensus estimate of $1.20 billion by 2.73 percent. This is a 1.12 percent increase over sales of $1.15 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

Graham Hldgs Q1 Adj. EPS $11.64 Beats $11.29 Estimate, Sales $1.17B Miss $1.20B Estimate

Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) reported downbeat first-quarter 2025 <a href="https://www.benzinga.com/quote/SPOT/earnings">financial results on Tuesday</a>.
Spotify reported quarterly earnings of $1.13 per share, which missed the analyst consensus estimate of $2.33. The company reported quarterly sales of $4.41 billion (4.19 billion euros), up by 15% year-on-year, which beat the analyst consensus estimate of $4.20 billion.
Spotify clocked monthly average user (MAU) net additions of 3 million quarter-over-quarter to 678 million, which is in line with the guidance.
Spotify said it expects fiscal second-quarter 2025 revenue of $4.52 billion (4.3 billion euros) versus an analyst consensus estimate of $4.39 billion and total MAUs of 689 million.
Spotify shares fell 3.5% to close at $576.94 on Tuesday.
These analysts made changes to their price targets on Spotify following earnings announcement.
<ul>
<li>Rosenblatt analyst Barton Crockett maintained Spotify Technology with a Neutral rating and lowered the price target from $658 to $657.</li>
<li>Evercore ISI Group analyst Mark Mahaney maintained the stock with an Outperform rating and lowered the price target from $700 to $650.</li>
</ul>
Considering buying SPOT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30083810/image-234-1024x585.png" alt="" class="wp-image-894854" style="width:562px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30083810/image-234-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30083810/image-234-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30083810/image-234-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30083810/image-234.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

SPOT

Spotify Analysts Slash Their Forecasts After Q1 Earnings

WIIM

Tradeweb Markets shares are trading higher. The company reported Q1 financial results.

Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) will report its second-quarter earnings on Wednesday. As the company reports after market hours, Wall Street expects $2.81 in EPS and <a href="https://www.benzinga.com/topic/semiconductors">$10.65 billion in revenues</a>.
The stock is down 11.44% over the past year, 4.40% YTD. Despite the decline, Qualcomm stock has been an outperformer in the chip sector so far this year. The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) is down over 15% YTD while the VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) is down 14%.
Wednesday's post-close earnings will put that momentum to the test. Beyond the headline numbers, Wall Street is laser-focused on two flashpoints: the potential impact of renewed Trump-era tariffs and any hints about Apple Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) <a href="https://benzinga.com/etfs/specialty-etfs/25/02/43888012/apples-in-house-modem-chip-sparks-qualcomm-concerns-3-etfs-with-key-exposure">expected phase-out of Qualcomm's modem chips</a>.
Let&#8217;s examine the charts for Qualcomm stock and how it currently compares to Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/25/04/45006138/smarter-cars-ahead-visteon-qualcomm-unveil-ai-cockpit-system">Visteon, Qualcomm Unveil AI Cockpit System For Smart Cars</a>
<h2 class="wp-block-heading">QCOM Stock Chart Mixed Ahead Of Q2 Earnings</h2>
Qualcomm stock is treading water ahead of earnings, with technical indicators painting a mixed picture for investors.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0430"><img loading="lazy" decoding="async" width="627" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30064138/Screenshot-2025-04-30-at-4.10.36-PM.png" alt="" class="wp-image-894586" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30064138/Screenshot-2025-04-30-at-4.10.36-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30064138/Screenshot-2025-04-30-at-4.10.36-PM-300x234.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0430">Chart created using Benzinga Pro</a>
Qualcomm stock, at $146.88, is showing slight selling pressure and a relatively stagnant trend. However, short-term momentum leans bullish, with Qualcomm trading above its eight-day and 20-day simple moving averages ($142.78 and $140.07, respectively). This positioning typically suggests underlying strength and potential for a near-term move higher.
That said, medium- to longer-term signals flash caution. Qualcomm stock is still below its 50-day simple moving average of $151.38 and well beneath its 200-day simple moving average of $163.63 &#8211; both bearish indicators that imply resistance and a broader downtrend. 
The Moving Average Convergence Divergence (MACD) sits at a negative 1.61, reinforcing the bearish undertone, while the Relative Strength Index (RSI) at 52.22 signals a neutral stance, suggesting QCOM stock is neither overbought nor oversold. 
For investors, this setup suggests cautious optimism in the short term, but a clearer breakout or breakdown post-earnings could be needed to set the tone for what's next.
<h2 class="wp-block-heading">Qualcomm Analysts See Over 10% Upside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/QCOM/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Qualcomm stock stands at a Buy currently with a price target of $193.41 a share. The latest analyst ratings from JPMorgan, Citigroup and TD Cowen imply a 10.39% upside for QCOM stock.
Price Action: Qualcomm stock closed the trading day Tuesday at $146.88, down 0.50%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/25/04/45094345/as-chinas-manufacturing-contracts-beijing-releases-defiant-video-calling-us-a-paper-tiger-and-vows-to-never-kneel-to-trumps-trade-war">As China&#8217;s Manufacturing Contracts, Beijing Releases Defiant Video Calling US A &#8216;Paper Tiger&#8217;</a></li>
</ul>
Image: Shutterstock

Technicals

Previews

Tech

AAPL

QCOM

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Qualcomm Stock Momentum Faces A Midweek Stress Test — Apple, Tariffs To Blame?

Pershing Square Holdco, L.P. ("Pershing Square"), the parent holding company of Pershing Square Capital Management, L.P. ("PSCM"), today announced that PSCM has further extended the term of its standstill agreement with Howard Hughes Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HHH#NYSE">HHH</a>) ("HHH") to facilitate ongoing discussions regarding the proposal previously announced by Pershing Square on February 18, 2025 and potential alternatives. On April 29, 2025, the term of the standstill agreement was extended from 5:00 p.m. (Eastern Time) on April 30, 2025 to 5:00 p.m. (Eastern Time) on May 30, 2025.

PSCM Extends Term Of Standstill Agreement With Howard Hughes Holdings To Facilitate Ongoing Discussions On Previous Proposal By Pershing Square And Potential Alternatives

Biotech

General

Oncocyte Announces Trial Progress, Completes Trial Design And Receives IRB Approval; Says Within Coming Weeks It Expects To Welcome Three Transplant Centers As Trial Participants

Better Choice Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#NYSE">BTTR</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRXH#NYSE">SRXH</a>) ("Better Choice" or the "Company"), a leading global health and wellness company, today announced completing its name change to SRx Health Solutions Inc. and the start of trading under the new ticker symbol ‘SRXH' today, Wednesday, April 30, 2025. The Company will continue trading on the NYSE American stock market under the new symbol, and no action is needed by current shareholders.
This name and ticker change follows the successful closing of the business combination between Better Choice Company and SRx Health, pursuant to which the combined company will emerge as a leading global health and wellness company committed to delivering better products and solutions for pets, people, and families.

BTTR

SRXH

Better Choice Company Announces Completion Of Name Change To SRx Health Solutions; Begins Trading Under The Ticker Symbol SRXH Today, Wednesday, April 30, 2025

Humana shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

Equitable Holdings shares are trading lower following a Q1 adjusted EPS miss.

JTAI

Jet.AI Signs LOI With Consensus Core To Pursue Development Of Two Hyperscale Data-Center Campuses

Western Digital shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results and issued Q4 adjusted EPS guidance above estimates. Additionally, the company declared a quarterly dividend of $0.10 per share.

NBIS

DDN Partners With Nebius To Deliver Seamless Performance For Enterprise AI Workloads

CLRB

CLRB stock has given up its prior gain. Cellectar Biosciences shares were trading higher after the company announced a plan to explore strategic alternatives.

<ul>
<li>Final marketing authorization decision for early-stage breast cancer is expected upon the FDA's approval of&nbsp;IceCure's post-market study plan</li>
<li>IceCure to engage with potential clinical sites, breast surgeons and radiologists for the post-market study including at the upcoming American Society of Breast Surgeons (ASBrS) Annual Meeting</li>
<li>ProSense&#xAE; would become the first-in-class minimally invasive choice—a major advancement in women's health and a new paradigm in breast cancer care as a simple out-patient procedure</li>
<li>U.S. sales and distribution team ready to drive sales of&nbsp;ProSense&#xAE; systems and disposable probes—supporting medical community and patients looking for a new minimally invasive option to lumpectomy</li>
</ul>
<a href="https://icecure-medical.com/">IceCure Medical Ltd.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it concluded a productive meeting with the leadership of the U.S. Food and Drug Administration's ("FDA") Center for Devices and Radiological Health ("CDRH") regarding the Company's De Novo marketing authorization request for ProSense&#xAE; in the treatment of early-stage low risk breast cancer when combined with adjuvant endocrine therapy for women aged 70 and over which represents approximately 46,000 patients annually in the U.S.
During the meeting, the FDA requested that IceCure conduct a study after marketing authorization has been granted ("the post-market study"), with the aim of producing additional data in this indication. IceCure will present its post-market study plan, which is expected to include a minimum of 400 patients at 25 sites, to the FDA, and upon the CDRH's approval of such plan, the FDA's final marketing authorization decision is expected.
IceCure is now working diligently on the plan of the post-market study which IceCure plans to submit in approximately a few weeks. The Company is in the process of recruiting clinical sites and doctors across the U.S., including at the American Society of Breast Surgeons (ASBrS) Annual Meeting which takes place April 30 – May 4, 2025. The Company believes this post-market study will support accelerated market adoption of ProSense&#xAE; in early-stage breast cancer.
"This is a very positive development, and we are pleased to have had such a positive discussion with the FDA's CDRH leadership so that women aged 70 and over across America can have access to a minimally invasive option for early-stage breast cancer with ProSense&#xAE;," stated Eyal Shamir, IceCure's Chief Executive Officer. "We are laser focused on the plan of our post-market study and look forward to finalizing it following deep engagement with the leading breast surgeons and radiologists in the U.S., including at ASBrS this week. As such, the meeting with the FDA is very well timed. We look forward to the FDA's approval of our post-market study plan and final marketing authorization decision for ProSense&#xAE; in this indication. Our U.S. sales team is ready for commercialization."

ICCM

IceCure Medical  Announces Meeting With Leadership Of The U.S. Food And Drug Administration's Center For Devices And Radiological Health Regarding The Company's De Novo Marketing Authorization Request For Prosense In The Treatment of Early-Stage Low Risk Breast Cancer When Combined With Adjuvant Endocrine Therapy For Women Aged 70

Benchmark analyst Cody Acree upgrades Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) from Hold to Buy and announces $95 price target.

Upgrades

QRVO

Benchmark Upgrades Qorvo to Buy, Announces $95 Price Target

D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) with a Buy and maintains $17 price target.

IMUX

D. Boral Capital Maintains Buy on Immunic, Maintains $17 Price Target

Svenska Handelsbanken (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SVNLY#OTC">SVNLY</a>) reported quarterly earnings of $0.15 per share which missed the analyst consensus estimate of $2.97 by 94.95 percent. This is a 6.25 percent decrease over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $1.38 billion which missed the analyst consensus estimate of $14.60 billion by 90.52 percent. This is a 6.11 percent decrease over sales of $1.47 billion the same period last year.

SVNLY

Svenska Handelsbanken Q1 EPS $0.15 Misses $2.97 Estimate, Sales $1.38B Miss $14.60B Estimate

Press Releases

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

Revolution Medicines to Participate in March 2025 Investor Conferences

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

Health Care

Revolution Medicines to Participate in April 2025 Investor Conferences

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Barbara Weber, M.D., Elected to ITM Supervisory Board

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

Comments

Revolution Medicines

Revolution Medicines (RVMD) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL